Triphase Accelerator Corporation, a private drug development accelerator dedicated to advancing compelling, well-differentiated drugs through Phase II proof-of-concept, today announced preclinical study results demonstrating that the combination of marizomib, Triphase’s highly-differentiated proteasome inhibitor, and pomalidomide (Pomalyst®) was synergistic in killing multiple myeloma cells. The marizomib data will be presented on Monday, June 2, in a poster session at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago.
Help employers find you! Check out all the jobs and post your resume.
